Abstract
Xerostomia, commonly known as dry mouth, is a significant complication in patients with Sjögren's syndrome (SS), an autoimmune disorder primarily affecting the salivary glands. This comprehensive review discusses the various management strategies available to alleviate xerostomia symptoms, including pharmacological and non-pharmacological approaches. Pharmacological treatments, such as cholinergic agents (pilocarpine and cevimeline), have shown effectiveness in stimulating salivary secretion, while topical therapies, like saliva substitutes, provide temporary relief. Non-pharmacological methods, including salivary gland stimulation through chewing gum and dietary modifications, offer additional symptom control. Emerging therapies, such as gene and stem cell therapy, hold promise for future treatment. A multimodal approach tailored to the individual needs of the patient is essential for the optimal management of xerostomia in SS, ultimately improving patients' quality of life. The review highlights the importance of ongoing research into novel therapeutic approaches to enhance treatment outcomes.